HC Wainwright Analysts Lower Earnings Estimates for Septerna

Septerna, Inc. (NASDAQ:SEPN) – Equities research analysts at HC Wainwright lowered their FY2025 earnings estimates for shares of Septerna in a report released on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($1.53) per share for the year, down from their prior estimate of ($1.45). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna’s Q4 2025 earnings at ($0.16) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.61) EPS and FY2026 earnings at ($1.67) EPS.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The company had revenue of $21.50 million for the quarter, compared to analysts’ expectations of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%.

Several other research analysts also recently commented on SEPN. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. Jones Trading started coverage on Septerna in a report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 price objective for the company. Truist Financial began coverage on shares of Septerna in a research report on Monday, December 15th. They issued a “buy” rating and a $34.00 price objective for the company. Raymond James Financial began coverage on Septerna in a research report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 target price on the stock. Finally, Wall Street Zen lowered Septerna from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Septerna presently has an average rating of “Moderate Buy” and a consensus price target of $33.83.

Septerna Stock Up 1.2%

Septerna stock opened at $26.67 on Thursday. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -17.66 and a beta of 3.85. The firm’s fifty day moving average is $26.71 and its 200 day moving average is $19.65. Septerna has a 52-week low of $4.17 and a 52-week high of $30.50.

Insider Transactions at Septerna

In related news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the sale, the senior vice president directly owned 92,911 shares of the company’s stock, valued at $1,677,972.66. This represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. purchased a new position in shares of Septerna during the 3rd quarter worth approximately $673,000. PharVision Advisers LLC boosted its stake in shares of Septerna by 17.5% during the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after purchasing an additional 1,780 shares during the last quarter. VR Adviser LLC boosted its holdings in shares of Septerna by 13.0% during the third quarter. VR Adviser LLC now owns 610,808 shares of the company’s stock worth $11,489,000 after purchasing an additional 70,355 shares during the last quarter. Verition Fund Management LLC purchased a new stake in shares of Septerna in the third quarter valued at $379,000. Finally, Millennium Management LLC increased its stake in Septerna by 639.6% in the third quarter. Millennium Management LLC now owns 384,200 shares of the company’s stock valued at $7,227,000 after purchasing an additional 332,256 shares during the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.